Table IV.
Antimicrobial resistance profiles of bacterial isolates (n = 21) at JMC, Jimma, Southwest Ethiopia, from July 2021 to October 2021
| Bacterial isolates | Total isolate | Resistance pattern of antimicrobial agents (%) |
||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CLR | CN | AMI | TET | CTR | CIP | SXT | CAZ | MEM | IMI | AMP | CFO | P | CLI | ERY | ||
| K. pneumoniae | 5 | 0 | 2 (40) | 1 (20) | 3 (60) | 3 (60) | 2 (40) | 3 (60) | 2 (40) | 3 (60) | 0 | NA | NA | NA | NA | NA |
| P. aeruginosa | 6 | 5 (83) | 6 (100) | 3 (50) | 6 (100) | 6 (100) | 5 (83) | 6 (100) | 6 (100) | 5 (83) | 4 (66.7) | NA | NA | NA | NA | NA |
| Acinetobacter spp | 3 | 1 (33.3) | 1 (33.3) | 2 (66.7) | 2 (66.7) | 3 (100) | 2 (66.7) | 2 (66.7) | 3 (100) | 1 (33.3) | 0 | NA | NA | NA | NA | NA |
| K. aerogenes | 2 | 1 (50) | 0 | 0 | 0 | 2 (100) | 1 (50) | 2 (100) | 2 (100) | 1 (50) | 0 | NA | NA | NA | NA | NA |
| Citrobacter koseri | 1 | 0 | 0 | 0 | 0 | 1 (100) | 1 (100) | 1 (100) | 1 (100) | 0 | 0 | NA | NA | NA | NA | NA |
| K. oxytoca | 1 | 1 (100) | 0 | 1 (100) | 1 (100) | 1 (100) | 1 (100) | 1 (100) | 0 | 0 | 0 | NA | NA | NA | NA | NA |
| Total | 18 | 8 (44.4) | 9 (50) | 7 (39) | 12 (66.7) | 16 (88.9) | 12 (66.7) | 15 (83) | 14 (77.8) | 10 (55.5) | 4 (22.2) | NA | NA | NA | NA | NA |
| CoNS | 3 | 1 (33.3) | 1 (33.3) | NA | 2 (66.7) | NA | 2 (66.7) | 1 (33.3) | NA | NA | NA | 2 (66.7) | 2 (66.7) | 3 (100) | 1 (33.3) | 2 (66.7) |
CoNS Coagulase-negative staphylococci, NA not applicable, CLR chloramphenicol, CN gentamicin, AMI amikacin, TET tetracycline, CTR ceftriaxone, CIP ciprofloxacin, SXT sulfamethoxazole-trimethoprim, CAZ ceftazidime, MEM meropenem, IMI imipenem, AMP ampicillin, CFO cefoxitin, ERY erythromycin, P penicillin, CLI clindamycin.